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Background: Cervical cancer is the fourth most common cancer in women worldwide, but the 
incidence has rapidly declined in developed countries after the introduction of structured 
screening programs. This disease is caused by persistent HPV infection commonly acquired in 
adolescence, thereby affecting young women. In countries with established screening 
programs, early detection has resulted in favorable prognosis. Surgical treatment is the main 
treatment for early-stage disease and radical hysterectomy (RH) cures more than 90% of those 
afflicted. However, this treatment is associated with considerable morbidity and impaired 
quality of life (QoL). In 2005, robot-assisted laparoscopic radical hysterectomy (RRH), was 
introduced and subsequently implemented in Sweden. The perceived benefits of minimally 
invasive surgery (MIS), and of RRH in particular, have not been confirmed. It is therefore 
imperative to assess the efficacy and safety of this surgical technique, as well as short- and 
long-term adverse effects, particularly since long-term survival is expected. 
Aims: The overall aim was to investigate the oncologic safety of RRH. Secondary aims 
included assessment of surgical outcomes, health care costs and impact on QoL, bladder, 
bowel, sexual and lymphatic function after RRH. 
Methods: To assess the oncologic and surgical outcomes, two population-based studies were 
performed (Studies I and II). Study I included 304 women who underwent RH stage IA1-IIA 
during 2006-2015 at Karolinska University Hospital (KUH). Surgical and oncologic outcomes, 
as well as the costs of RRH and open radical hysterectomy (ORH) were compared. Study II, 
a nationwide cohort study, assessed overall and disease-free survival after RRH and ORH in 
864 women with stage IA1-IB1 disease. The functional impact of RRH was investigated in two 
prospective clinical studies (Studies III and IV) with one-year follow-up. In Study III, 26 
women undergoing RRH filled in a questionnaire regarding psychological well‐being and 
sexual, bowel, bladder, and lymphatic function. In addition, postoperative ovarian function 
was measured by change in sex hormones. In Study IV, 27 patient-reported outcomes after 
RRH were assessed using two validated questionnaires concerning bladder function and its 
impact on QoL. Outcomes were determined objectively by urodynamics and quantification of 





Results:  In the regional study (Study I), RRH was associated with an increased risk of 
recurrence (HR 2.13; 95% CI, 1.06-4.26). The postoperative complication rates (37%) and 
costs were similar, but the hospital stay was shorter than following ORH. The nationwide 
study (Study II) showed no statistical difference between RRH and ORH with respect to 5-
year OS (HR 1.00; 95% CI, 0.50-2.01) and DFS (HR 1.08; 95% CI, 0.66-1.78). Study III 
demonstrated that RRH had a minor effect on sexual function, as well as bowel function. 
However, bladder impairment and lymphedema remained the main dysfunctions associated 
with RRH for cervical cancer (Studies III and IV). No correlation between the number of 
autonomous nerves ablated and functional outcomes was observed. In general, postoperative 
urinary symptoms diminished over time, but persisted in a substantial proportion of the women 
and may impair QoL. 
Conclusions: RRH appears to be safe once surgical proficiency is achieved. Prospective trials 
are needed to ensure the safety of RRH for cervical cancer. RRH was associated with less 
perioperative morbidity, and health care costs were similar to those of ORH. RRH seems to 
have only minor effects on sexual function, though bladder dysfunction remains a significant 
sequele. The cause of functional impairment after RRH is multifactorial and cannot be 
explained by nerve ablation alone. 
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Early stage cervical cancer generally has a favorable prognosis and about half of the women 
are diagnosed under 50 years of age. Long term survivorship is therefore expected and 
treatment-induced morbidity and its impact on quality of life (QoL) is of considerable concern. 
Cervical cancer has traditionally been treated with open radical hysterectomy (ORH), a 
procedure often associated with major side-effects. Minimally invasive surgery (MIS) 
techniques by conventional laparoscopy were developed in the early 1990´s and in 2005 
treatment of gynecological cancer by robot-assisted surgery was approved by the Food and 
Drug Administration (FDA). In Sweden traditional ORH for cervical cancer has gradually been 
replaced by robot-assisted radical hysterectomy (RRH). (Figure 1) 
To date, few investigations have focused on comparing ORH and MIS with respect to efficacy, 
safety and survival, as well as impact on QoL. In this context, two major publications in 2018 
(1, 2) raised serious concerns about the oncologic safety of minimally invasive radical 
hysterectomy (RH), including RRH. Since 2019, the National Comprehensive Cancer Network 
(NCCN), as well as the European Society of Gynecological Oncology (ESGO) recommend RH 
with an open approach as the gold standard treatment (3, 4). 
The four studies in this thesis aimed to investigate the oncological safety (Studies I and II), as 
well as surgical outcomes (Study I) and functional consequences (Studies III and IV) after 




Figure 1. The numbers of open (ORH) and robot-assisted (RRH) radical hysterectomies for early-































2.1 EPIDEMIOLOGY, ETIOLOGY AND PREVENTION 
Cervical cancer is the fourth most common cancer worldwide and the most common 
gynecological cancer, affecting approximately 500,000 women annually (5) (Figure 2). In 
contrast to the high incidence worldwide, the incidence has fallen dramatically in developed 
countries as a consequence of structured screening programs (6). In Sweden, nearly two-thirds 
of incident cases occur among women who have not participated in the screening program (7). 
Early detection has resulted in a generally favorable prognosis, with reported survival ranging 




Figure 2. The estimated age-standardized incidence rates of cervical cancer globally in 2018. Data 
source: GLOBOCAN 2018, Graph production: IARC (http://gco.iarc.fr/today) World Health Organi-
zation. 
 
Human papilloma virus (HPV), which is transmitted sexually, is detected in the majority of all 
cervical cancers and thus considered to be the causal factor (11). The carcinogenic properties 
of HPV are primarily due to two viral proteins, E6 and E7, which by intracellular binding to 
p53 and retinoblastoma proteins prevent apoptosis and provoke unregulated proliferation (12). 
Infection with HPV can cause low- or high-grade intraepithelial lesions that usually heal 
without intervention, though persistent infections may progress to cancer (13, 14). The risk of 




Primary prevention by vaccination against HPV reduces the development of precancerous 
lesions by an estimated 80% (18) and cervical cancer by 70% (19). Bivalent, quadrivalent and 
ninevalent vaccines all protect against HPV types 16 and 18, which are the most common sub-
types inducing precancerous lesions (20-22). In Sweden, vaccination is offered to girls 10-12 
years of age and since 2020, also to boys. 
The World Health Organization (WHO) has stated its ambition to reduce the incidence of 
cervical cancer to <4/100,000 during the 21st century through vaccination of 90% of  all girls 
by the age of 15 (23). At the same time, Australia instigated an ambitious program of 
vaccination in 2007 (including boys in 2013) designed to attain this same goal somewhere 
between 2021 and 2035 (24).  
The nation-wide screening program in Sweden, updated in 2018, has effectively reduced the 
incidence of cervical cancer by identifying precancerous lesions, as well as early-stage tumors    
(19, 25, 26). All women between the ages of 23 and 65 are invited to participate. Women 30-
65 years of age are tested for the presence of HPV, while those 23-29 years old are triaged for 
testing for precancerous lesions with liquid-based cytology and, if the findings are positive, are 
then tested for HPV (25). Ongoing research focuses on prevention with a vaccine directed 
against the viral proteins E6 and E7, which can hopefully even reverse precancerous lesions 
(27). 
Unfortunately, the incidence of cervical cancer in Sweden increased by approximately 100 
cases/year between 2014 and 2018 (28). Increased awareness of the unreliability of cytology 
testing alone has resulted in an updated screening program with more testing of HPV, which 
detects pre-stages of cervical cancer more accurately (25, 29). (Figure 3) 
 
 
Figure 3. Incidence of cervical cancer /100000 population (left) and mortality from cervical cancer 
(right) in Sweden 1960-2010. Source: NORDCAN https://www-dep.iarc.fr/nordcan/sw/frame.asp 
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2.2 HISTOPATHOLOGY AND PROGNOSTIC FACTORS 
The stage of the tumor and lymph node status are the most important independent determinants 
of the prognosis for women with cervical cancer. The 5-year survival for node -negative stage 
IB1 disease is approximately 95% but drops to 78% with node-positive disease (30, 31). The 
risk of lymph node metastases increases with larger tumors (32, 33) and a more advanced stage 
(34).  
The two main histopathological types of cervical cancer are squamous cell carcinoma (75% of 
the cases in Sweden) and adenocarcinoma (25%). An increased incidence of adenocarcinoma 
has been reported and may partially be explained by the use of oral contraceptives (35, 36). 
Squamous cell carcinoma can be further categorized as keratinizing, non-keratinizing, basaloid, 
verrucous, warty, papillary, lymphoepithelioma-like or adenosquamous. The subtypes of 
adenocarcinoma include mucinous, endometroid, clear cell, serous, villoglandular and 
mesonephric. Other histopathological types, including neuroendocrine tumors, clear cell cancer 
and sarcoma, are rare and require individualized treatment.  
Findings concerning whether histopathological type is associated with survival are inconsistent 
(30). However, the Swedish Quality Register for Gynecologic Cancer (SQRGC) recently 
reported that survival is independent of histopathological type (except for rare histotypes). 
Tumor extension beyond the cervix, e.g. involvement of the parametria, is known to be a risk 
factor for poor outcome (37).  Other risk factors include involvement of the lymph vascular 
space (LVSI) and depth of invasion into the cervical stroma (38, 39). As is the case for most 
solid tumors, increasing age is associated with poorer prognosis, although there is no indication 
that the biology of the disease in younger and older women differs. However, younger women 











In the present thesis, staging of cervical cancer is based on the 2009 International Federation 
of Obstetrics and Gynecology (FIGO) classification (40) that preceded the current system 
(FIGO 2018) (41). In contrast to the more recent system, the  classification from 2009, based 
on clinical examination under anesthesia, does not consider findings from advanced imaging,  
but does take into consideration the results of basic chest X-rays, urography, cystoscopy and/or 
rectal scanning (42).  
Since the earlier clinical staging does not take into account the presence or absence of lymph 
node metastases, the actual stage of the disease was often underestimated (43, 44). Therefore, 
since January of 2020 (41), the new system of staging, including imaging in combination with 
clinical and histopathological findings is being utilized in Sweden (41). In addition, tumors <2 
cm in size (IB1) are now considered separately from those 2-4 cm in size (IB2). For further 
information regarding the new staging system see Table 1. 
Use of the Classifications of Malignant Tumors (TNM) in combination with the FIGO system 
is encouraged. The TNM involves standard classification of solid tumors on the basis of the 

















Table 1. Comparison of TNM classification of cervical carcinoma with staging according to FIGO in 
2009 and 2018. Changes are marked in red. Adapted from (40, 41) and used with the kind permission 
of Dr. Pálsdóttir. 
TNM 2018 2009  
T1 I I  The carcinoma is strictly confined to the cervix (extension to the 




 IA  Invasive cancer identified only microscopically (All gross lesions 
even with superficial invasion are Stage IB 
cancers). Stromal invasion is limited to maximal depth of 5 mm and  
width of 7 mm 
T1a1   IA1  Measured invasion of stroma ≤ 3 mm in depth (and ≤ 7 mm width) 
T1a1  1A1  Measured invasion of stroma ≤ 3 mm 
T1a2   IA2  Measured invasion of stroma > 3mm and < 5 mm in depth (and ≤ 7 
mm width) 
T1a2  1A2  Measured invasion of stroma >3 mm and ≤ 5 mm 
T1b  
 




IB  Invasive carcinoma with measured deepest invasion ≥ 5 mm 
(greater than IA) 
T1b1   IB1  Clinical lesions no greater than 4 cm in size 
T1b1  
 
IB1  Invasive carcinoma with ≥ 5 mm depth of stromal invasion, and 
largest dimension < 2 cm 
T1b2   IB2  Clinical lesions > 4 cm in size 
T1b2  IB2  Invasive carcinoma with a largest dimension ≥2 and <4 cm  
T1b3  IB3  Invasive carcinoma ≥4 cm in largestdimension 
T2  
 
II II  The carcinoma extends beyond the uterus, but has not extended 
onto the pelvic wall or the lower third of the vagina 
T2a  
 
IIA IIA  Involvement of as much as the upper 2/3 of the vagina. No obvious 
parametrial involvement 
T2a1  IIA1 IIA1  Invasive carcinoma with largest dimension <4 cm 
T2a2  IIA2 IIA2  Invasive carcinoma with largest dimension ≥4 cm  
T2b  IIB IIB  Parametrial involvement, but not into the pelvic sidewall 
T3  
 
III III  The carcinoma has extended onto the pelvic sidewall. On rectal 
examination there is no free space between the tumor and pelvic 
sidewall. The tumor involves the lower third of the vagina. All cases 
of hydronephrosis/nonfunctioning kidney should be included unless 
they are known to be due to other causes 
T3a  
 








IIIC  Involvement of pelvic and/or paraaortic lymph nodes, irrespective of 
tumour size and extent (with r=radiology and p=pathology notations) 
 IIIC1   Involvement of pelvic lymph nodes 
 IIIC2  Involvement of paraaortic lymph nodes 
T4  
 
IV IV  The carcinoma has extended beyond the true pelvis or has clinically 
involved the mucosa of the bladder and/or rectum 
 
 
  The carcinoma has extended beyond the true pelvis or has clinically 
involved the mucosa of the bladder and/or rectum (Biopsy proven) 
T4a  IVA IVA  Spread to adjacent pelvic organs 






The intent of primary treatment for early-stage cervical cancer is curative, with excellent 
survival regardless of treatment modality. There are two principally different treatment 
strategies: primary surgery or definitive chemoradiation (46). The only randomized controlled 
trial (RCT) comparing surgery and radiotherapy without concomitant chemotherapy was 
performed more than 30 years ago and included 343 patients with stage IB and IIA cervical 
cancer (52). No difference in survival was observed and no conclusion regarding preferred 
treatment drawn. Interestingly, primary surgery was associated with more morbidity and 
women who underwent surgery followed by adjuvant radiation did worst in terms of functional 
outcomes.  
Maximal effort must be made to identify factors that indicate against treatment with both 
surgery and adjuvant radiotherapy (46). At the same time, surgery has remained the primary 
mode of treatment for tumors confined to the cervix and is recommended by most international 
societies. Surgery allows full nodal examination, the strongest prognostic factor, and 
chemoradiation can be reserved for treatment of recurrence. In a modern setting, the relevance 
of that earlier trial (46)  is questionable, since both surgical and non-surgical treatments have 
been refined considerably. In addition, preoperative staging has improved dramatically, with 
the introduction of advanced imaging minimizing the risk of under-staging the disease. 
In Sweden, definitive chemoradiation, including external beam radiation therapy (EBRT) in 
combination with intracavitary radiotherapy (brachytherapy) and weekly chemotherapy with 
cisplatin, is recommended for cervical cancer of stages IB3 and IIA2-IV4. The total external 
radiotherapic dose is 45-50 Gray (Gy) in the case of the lymph nodes and 50-56 Gy for the 
tumor target, both delivered at 1.8-2.0 Gy daily for 5-6 weeks (47, 48). 
Early stages (IA1, IA2, IB1, IB2, IIA1 according to FIGO 2018 (41)) of cervical cancer are 
treated surgically by conization, simple hysterectomy or RH with pelvic lymphadenectomy 
(PLND), depending on the stage and characteristics of the tumor. In the case of stage IA1-2, 
conization or simple hysterectomy is sufficient, with supplementary PLND when LVSI is 
present. In tumors <2 cm in size and without aggressive histology, surgery designed to preserve 
fertility (trachelectomy) with pelvic lymph node assessment is an option.  
Radical trachelectomy can be performed abdominally, vaginally or by MIS modalities, with all 
three approaches demonstrating oncologic safety comparable to that of traditional RH (49, 50). 
RH with PLND is recommended for stages 1B1-2 and IIA1. Although ovarian involvement is 
rare, removal of the ovaries (BSO=bilateral salpingo-oophorectomy) should be considered in 
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the case of adenocarcinomas and tumors with histological characteristics associated with high 
risk (51). 
The indications for adjuvant treatment are primarily based on a RCT performed in 1999. 
Several adverse prognostic factors were identified and women with tumors larger than 4 cm, 
extension deep into the cervical stroma and LVSI benefited from adjuvant radiation (52). For 
high-risk tumors, Peters (54) found an improved OS with chemoradiation compared to 
radiation alone. The significance of close tumor margins has so far been poorly explored, but 
the general consensus is to offer adjuvant treatment when the margin is inadequate (< 5mm) 
(53, 54). The strongest prognostic factors for recurrence are stage, presence of lymph node 
metastasis and tumor size (33, 55). Adjuvant treatment has been demonstrated to reduce local 
recurrences in women with node-positive disease (56). 
In an era of constantly evolving treatment options for women with early-stage cervical cancer, 
it becomes increasingly clear that current recommendations in this context are based on 
relatively weak scientific evidence. The few relevant RCTs were conducted more than 20 years 
ago (46, 52, 55) and do not reflect current practice. Notable changes during the past decades 
include the introduction of advanced imaging and MIS, addition of chemotherapy and 
refinement of external beam therapy  (55, 57, 58). More recently advancements in 
brachytherapy, with the incorporation of image guidance and interstitial therapy, promise 
improved survival and QoL  (59, 60). These changes should clearly be evaluated and 
considered with respect to the debate on surgical treatment of early-stage cervical cancer. 
2.4.1 Surgical treatment of cervical cancer 
In addition to traditional laparotomy (61), there are several surgical approaches to RH, 
including vaginal radical hysterectomy (62), MIS by conventional laparoscopy (63) and robot-
assisted laparoscopic surgery (RRH) (64, 65). 
The primary aim of surgery is to achieve tumor-free margins and thereby cure the patient. 
Adequate staging for prognostic purposes, as well as for deciding about whether to give 
adjuvant treatment is also essential. Considering that surgery is reserved for tumors confined 





2.4.1.1 Radical hysterectomy 
Radical hysterectomy, first performed by JG Clark in 1895 at Johns Hopkins School of 
Medicine (9, 66), has become the cornerstone of surgical treatment for early-stage cervical 
cancer. In order to achieve tumor-free margins when the tumor extended beyond the cervix and 
involved adjacent tissue, modification of the simple hysterectomy was necessary. The concept 
of RH was refined and described by the Austrian surgeon Ernst Wertheim in 1912, whose 500 
patients had an extraordinary 5-year survival rate of 42%  and only 18% mortality (66). In 
Japan, Hidekazu Okabayashi modified the technique further to include more extensive 
resection of the parametrial tissue through complete separation of the posterior leaf of the 
vesicouterine ligament to separate the ureter from the bladder (67).  
The improved local control provided by lateral extension of the RH (Figure 4) raised the 
awareness of the importance of regional lymph node assessment. In the 1950´s Joe Vincent 
Meigs added bilateral systematic dissection of lymph nodes in the pelvis (68). The indication 
for PLND remains diagnostic (34, 69), although relatively recent studies from Germany 
suggest that “therapeutic lymphadenectomy” is an alternative to adjuvant radiotherapy for 





Figure 4. Surgical specimen from a radical hysterectomy including uterus with adnexa and 
surrounding parametrial tissue and opened vagina. 
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Growing awareness of the sequelae observed after RH led to the development of a nerve-
sparing technique by the Japanese Takashi Kobayashi, where the splanchnic nerve was 
identified during dissection of the parametria (66). More recently, a novel concept related to 
compartmental dissemination of cervical cancer was proposed by Michael Höckel and co-
workers (72). Based on the hypothesis that tumors initially spread within their own 
morphogenetic unit, a procedure referred to as total mesometrial resection (TMMR) that can 
also be applied to locally advanced tumors (IIB) was developed. TMMR is accompanied by 
therapeutic lymphadenectomy and even though node-positive disease is not treated by 
radiotherapy, survival is equally good or better than that reported following standard RH with 
postoperative radiation (70). 
The lateral extension of hysterectomy first described by Wertheim was motivated by the 
observation that most cervical tumors extend beyond the cervix. With modern imaging, locally 
advanced tumors can be identified and subsequently treated with chemoradiation, a change that 
has prompted discussion about whether RH is still an appropriate treatment. Indeed, several 
studies, including an RCT, have demonstrated that survival following less radical surgery is no 
worse than with standard RH  (73-76).  
Data on the safety of treating small tumors (<2 cm) in the absence of other risk factors with 
less radical surgery is available (74, 77, 78). Parametric involvement is extremely rare with 
tumors less than 2 cm in size (≤IB1) and for these, surgical treatment with simple hysterectomy 
appears to be sufficient. In the ongoing SHAPE trial, for which results are expected in 2021, 
women with stage IA-IB1 disease are randomized to undergo either simple or radical 
hysterectomy (79). It has also been proposed that radical surgery can be replaced by 
neoadjuvant chemotherapy followed by fertility-preserving surgery (80).  
Historically, RRH was classified according to Piver-Ruthledge system (81), but in 2009 
Querleu-Morrow introduced a new system that takes into account the three- dimensional 
anatomy of the pelvis (82). (Table 2) 
The European Society of Gynaecological Oncology (ESGO) has published guidelines in an 
attempt to improve and standardize the management of cervical cancer, where quality 






Table 2. Classification of radical hysterectomy according to Querleu-Morrow (82) 
 
Type Resection Mobilizati


















to the cervix  
Dissection close 
to the cervix 
B  Modified radical Partial Medial to the 
ureter 
10 mm  Partial resection  Partial resection  
C1  Classic radical Complete Lateral to the 
ureter. At the iliac 
vessels caudal 
part preserved  






C2 Classic radical Complete Lateral to the 
ureter. At the iliac 
vessels including 
caudal part 








D  Lateral extended  Complete At the exit of the  
a. iliaca interna, 
with exposure of 
the root to n. 
ischiadicus 





2.4.1.2 Nerve-sparing radical hysterectomy 
The uterus, urinary bladder, distal rectum and upper vagina are innervated by both the 
sympathetic and parasympathetic branches of the autonomic nervous system. The nerves of 
greatest importance are the sympathetic nerve fibers from the hypogastric nerve plexus and 
parasympathetic nerves from the pelvic splanchnic system (sacral roots S2-S4). The 
hypogastric plexus is divided into the inferior hypogastric nerve that follows the ureter past the 
sacrouterine ligaments. At the cardinal ligaments, the hypogastric fibers fuse with the pelvic 
splanchnic nerve (84). 
For maintaining bladder function both sympathetic and parasympathetic autonomic nerves 
must be preserved, including the hypogastric nerve, pelvic splanchnic nerve, inferior 
hypogastric plexus and vesical branches of the inferior hypogastric plexus. Unfortunately, 
certain aspects of RH can damage these important nerves (Figure 5). The transection of the 
uterosacral ligament may injure the hypogastric nerve and the splanchnic nerve needs to be 
identified during the dissection of the cardinal ligament (the lateral parametrium). Also, the 
inferior hypogastric plexus may be injured when the surgeon ligates and divides the vaginal 
blood vessels (85, 86). 
There are studies suggesting that nerve-sparing techniques reduce functional problems after 
RH (87-92). The modified classic RH, the type C1, is theoretically nerve-sparing if performed 
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according to the anatomical boundaries as described by Querleu-Morrow in 2008. In 2011, 





Figure 5. Nerves at risk during RRH. Adapted from (94), modified by M Santos. 
 
 
2.4.1.3 Minimally invasive radical hysterectomy 
The first laparoscopy was described in 1805 when Phillip Bozzini developed a cystoscope to 
examine canine bladder. Later, the Swedish surgeon Hans Christian Jacobaeus performed an 
experimental laparoscopic procedure in a dog. In the 1930s laparoscopy gained popularity in 
the US as a less invasive alternative to laparotomy and in1936, the first laparoscopic 
sterilization was performed by dr Boesh, a Swiss gynecologist (95). During the 1980´s, the 
1.Uterus 
2. Bladder 
3. Inferior hypogastric plexus  
4. Ureter  
5. Splanchnic nerve 






introduction of the video laparoscopy together with the development of better instruments 
revolutionized the technique (96). The first laparoscopic hysterectomy was performed in the 
late 1980s and large RCTs has later established the benefits of laparoscopy compared to 
traditional open hysterectomy for endometrial cancer (97-99). The first laparoscopic RH was 
described in 1992 (100) and subsequent case-series reported less postoperative pain and a 
shorter hospital stay (63, 100-108) compared to ORH. Two meta-analyses of retrospective data 
suggested superior outcomes for MIS. Wang with colleagues included twelve original studies 
(1539 women) comparing LRH with open technique where OS was similar between the two 
surgical modalities (92). In the same year, 2015, Shazly with colleagues included 26 
nonrandomized studies comparing MIS (LRH and RRH) with ORH and concluded better 
surgical outcomes for MIS as lower blood loss, shorter hospital stay. However, conventional 
laparoscopic RH has never been widely adopted in Scandinavia due to the relatively long 
learning curve, as well as ergonomic disadvantages (109, 110). 
In 2005 robot-assisted laparoscopy (RRH) was first approved by the Food and Drug Agency 
(FDA) for gynecological indications in the United States. The technology was rapidly adopted 
worldwide and in Scandinavia despite the high costs associated with the technology. Compared 
to traditional laparoscopy, robot-assisted laparoscopy offers improved visibility and greater 
surgical precision, as well as ergonomic advantages for the surgeon (111), less or similar 
complications and faster recovery (112, 113). The first RRH was performed in 2005 (114) and 
early experiences suggested benefits compared to the traditional open procedure in terms of 
shorter hospital stays, fewer complications and less blood loss (65, 101, 107, 110, 115-122).  
Observational studies further indicated that the oncologic outcomes following RRH and open 
procedures were similar (102, 107, 116, 118, 123-125). Most international societies including 
Swedish national guidelines (19), as well as the National Comprehensive Cancer Network 
(126) and ESGO (127), considered MIS to be safe and the recommended surgical approach for 
early cervical cancer, although RCTs were lacking. In 2008, the international, randomized 
controlled trial “Laparoscopic Approach to Cervical Cancer” (the LACC-trial) was initiated to 
explore the oncologic safety of MIS for early stage cervical cancer (128). The enrollment of 
study subjects was slow, and data was not available until 2018 after premature closure. In 
agreement with the results from the LAP2 and LACE trials, the LACC-trial was expected to 
show non-inferiority for MIS (97, 98). 
The LACC-trial finally enrolled 632 women with stage IA-IB1 cervical cancer and the primary 
endpoint was disease-free survival (DFS) at 4,5 years. The trial was never completed since the 
Data Safety and Monitoring Board observed a dramatic difference in DFS with inferior 
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outcome in the MIS arm compared to open approach (86.0% versus 96.5%, HR 3.74; 95% Cl, 
1.63-8.58) (1). In addition, the MIS arm was associated with an inferior OS of 93.8 % vs 99.0%, 
HR 6.00; 95% Cl, 1.77-20.30). The trial was immediately criticized on several aspects.  The 
main criticisms include the subjective assessment of surgical proficiency, the lack of central 
pathology and the slow accrual of study subjects from a total of 33 centers. In addition, the 
LACC-trial did not explicitly explore the safety of RRH and only 15.6% underwent this 
approach in the MIS arm.  
The surprising findings from the LACC trial have since the publication in 2018 been reinforced 
by observational data (129-133) (Table 3). Based on data from the National Cancer Database 
between 2010-2013 including 2203 women with stage 1A2-1B1 cervical cancer in the United 
States,  Melamed observed a 9.1% risk of death after MIS compared to a corresponding risk of 
5.3% after open surgery (HR 1.65, p=0.002) (2). A recent metanalysis included 15 high-quality 
retrospective studies encompassing 9499 patients, of whom 2675 underwent RRH, 2009 LRH 
and 4815 open surgery. The risk for recurrence or death after MIS was concluded to be higher 
than after open technique (HR 1.71, p<0.001). In a stratified analysis of the studies 
predominated by RRH, a higher risk of recurrence or death (HR 1.88 (Cl 1.36-2.60) was 
observed. In addition, a similar analysis of studies of LRH, the HR was found to be 1.54 (Cl 
1.10-2.16) Interestingly, only one out of five papers published prior to the LACC-trial 
suggested that RRH was inferior to ORH (134). 
Secondary endpoints from the LACC-trial have recently been published and challenge the 
perceived benefits of MIS for cervical cancer. In line with RCTs in endometrial cancer, most 
retrospective data have indicated that MIS confers less perioperative morbidity. However, no 
difference in either intra- nor postoperative adverse outcomes was observed in the LACC-trial 
(135). Interestingly, more nerve injuries and vaginal vault complications were observed in the 
MIS arm and as expected, a higher frequency of transfusions and wound complications in the 
open arm. 
Based on the results from the LACC-trial, RRH is no longer considered to be the standard 
treatment for early cervical cancer and most societies and national guidelines have changed 
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2.4.2 Lymph node assessment  
RH includes assessment of pelvic lymph nodes in order to identify regional tumor 
dissemination. Traditionally, systematic PLND, including the external iliac and obturator area, 
has been recommended for early-stage cervical cancer. In agreement with staging procedures 
for other malignancies, lymphadenectomy is associated with substantial morbidity, with 
lymphedema being the most important (137, 138). In addition, during PLND, nerve damage 
may occur and injuries to large vessels have been reported (139). Persisting lymphedema has 
a substantial impact on QoL and treatment options are limited (137, 140, 141).  
In connection with treatment of breast cancer, systematic lymphadenectomy has been replaced 
by detection of sentinel lymph nodes (SLN), which reduces morbidity dramatically (142). For 
cervical cancer, several investigations studies suggest that the adoption of SLN technique is 
feasible and allows highly sensitive detection of metastatic disease (143-145). Replacement of 
Tc99 with the novel tracer indocyanine green (ICG) has simplified the procedure considerably 
(146). In addition to the expected reduction in postoperative lymphedema, SLN allows 
improved histopathological analysis based on ultrastaging of retrieved nodes. However, 
survival data is lacking and results from an ongoing RCT comparing SLN with full 
lymphadenectomy (SENTICOL III) are not expected until 2027 (147). Based on current 
evidence, ESGO recommends usage of SLN only for stage IA cervical cancer and the recently 
revised Swedish guidelines include similar recommendations (127, 148).   
 
2.5 HEALTH CARE COSTS ASSOCIATED WITH SURGICAL TREATMENT 
Although the Swedish Agency for Health Technology Assessment and Assessment of Social 
Services (SBU) has described methods for calculating health care economics, no authority 
evaluates the costs of technical medical products used in Sweden (149). It is clear that the 
total cost for robot-assisted surgery in prostate cancer is higher than for traditional 
laparotomy (150, 151). Moreover, Lönnerfors and colleagues (152) concluded that robot-
assisted surgery for benign indications is associated with higher costs and several studies 
have shown that this is also the case for endometrial cancer (153, 154). However, Reynisson 
and Persson found that cost effectiveness for RRH can be achieved in high-volume settings 
(155). Clearly, comparison of different economic studies of this type is challenging because 
the costs included vary widely. Nonetheless, financial considerations remain a major concern 
when new technologies are introduced into the clinic (156). 
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2.6 FUNCTIONAL OUTCOMES AFTER SURGICAL TREATMENT OF 
CERVICAL CANCER 
Traditionally, evaluation of cancer therapy in clinical trials has been based on disease-free 
(DFS) and overall survival (OS), tumor response, and toxicity, but in the past few decades there 
has been an increased focus on the patient´s QoL, which is now also frequently assessed in 
clinical trials (157). The term QoL and, more specifically, Health Related Quality of Life (HR-
QOL), encompasses perceptions of both negative and positive aspects of at least physical, 
emotional, social and cognitive functions (158). In addition, QoL has been proposed to have 
an impact on survival  (159).  
HR-QoL is assessed subjectively through questionnaires of varying validity (i.e., measuring 
what is intended to be measured) and reliability (i.e., absence of errors). In cancer patients, the 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaires 
(EORTC QLQ-C30), has been developed (160). This 30-item multidimensional 
questionnaire whose validity and reliability have been confirmed in several studies (161, 
162), is frequently employed.  
There are also two instruments designed specifically to assess the QoL of patients with 
cervical cancer. The first of these is the Quality of Life module of the European Organization 
for Research and Treatment of Cancer, EORTC QLQ-CX24. This consists of 24 questions 
designed to evaluate body image, sexual activity and enjoyment, sexual and vaginal 
functioning, as well as symptoms associated with sexual experience, peripheral neuropathy, 
menopausal status, lymphedema, and sexual anxiety (163). In addition, the Functional 
Assessment of Cancer Therapy (FACT-Cx) was designed to assess the health-related quality 
of life of patients with cervical cancer (164). 
Most commonly, questionnaires are validated psychometrically. However, even if a 
psychometrically valid instrument describes the symptoms reliably, it is not designed to 
elucidate underlying causes. For this reason, Professor Gunnar Steineck at Sahlgrenska 
Academy developed a clinimetric approach for validation (165, 166). In this context each 
question undergoes an extensive face‐to‐face validation (sometimes called the “think‐aloud‐
method”) to ensure that the respondents understand correctly. Moreover, when the response 
rate has been too low in preparatory studies, the phrasing of questions has been adjusted to 




2.6.1 Psychological quality of life 
Results concerning the psychosocial well-being among survivors of cervical cancer have varied 
widely, due to differences in the questionnaires used, as well as the heterogeneity of 
participants with respect to tumor stage and treatment (167, 168). Following treatment, anxiety 
and mental fatigue are common (169-171), as is impaired fertility, which in itself is a risk factor 
for depression (172). Some studies have reported a higher incidence of divorce (173). A 
systematic review published in 2019 and including women in the Nordic countries who 
developed gynecological cancer concluded that even many years after treatment, these patients 
can still exhibit lowered physical, mental and psychosocial well-being (174).   
In colon cancer, RCTs support that MIS does not affect HR - QoL to the same extent as open 
surgery (175, 176). However, in gynecological cancer, the evidence to date reveals no 
difference between RRH and ORH (177, 178). The LACC trial support the conclusion that 
QoL following treatment of cervical cancer with MIS or open surgery does not differ (179).  
2.6.2 Sexual function 
Survivors of cancer are at risk of impaired sexual function with reduced desire, arousal and 
sexual satisfaction (166, 180-182). This is also the case for women who undergo ORH for 
cervical cancer. Decreased desire can probably be explained, at least in part, by the stress 
associated with diagnosis and treatment. However, if autonomous nerves are damaged during 
the surgical procedure, vaginal blood flow, swelling of the genitals and lubrication may also be 
reduced (88, 182-186). Furthermore, following treatment the vagina can become shortened and 
less elastic due to fibrosis and adhesions, leading to pain during intercourse (166, 187, 188). 
Such  symptoms have been observed after both ORH (88, 182) and LRH (89, 111, 189). A 
systematic review published in 2012 concluded that impaired sexual function in survivors of 
cervical cancer is almost always accompanied by pain during intercourse, while the capacity to 
experience orgasm (sexual satisfaction) often remains intact. Therefore, impaired arousal could 
be primarily a result of dyspareunia. Again, comparison of the results of different investigations 
on the QoL and sexual function of survivors of cervical cancer is challenging because of the 
variety of questionnaires used and differences in the inclusion criteria and, consequently, in the 
patient populations involved (190).  
2.6.2.1 Assessment of sexual function 
Female sexual function can be assessed with questionnaires, interviews and/or log books. Due 
to the shortage of validated questionnaires in this area, it is difficult to compare the results of 
different studies. In addition, the multi-dimensional nature of sexual function, with its 
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psychological, physiological and cultural aspects, even makes it more challenging to assess. 
The Female Sexual Function Index (FSFI) has been validated under a range of clinical 
conditions, including cervical cancer, and is widely used. It is available in Swedish (191, 192). 
However, this index has only been validated for sexually active, and not for sexually inactive 
women. Two other questionnaires in this area, the Leiden Questionnaire (193) and the Sexual 
Function–Vaginal Changes Questionnaire (194), have still to be validated for use in Sweden. 
Objective assessment of genital response through determination of local blood flow in the 
vagina with photoplethysmography has shown that RH reduces this blood flow more than 
simple hysterectomy (195, 196). Attempts have been made to measure the clitoral volume by 
MRI (197) or assess the temperature of the labia during sexual stimulation (198). 
2.6.3 Bladder function 
Bladder function consists of storage and voluntary voiding. Voluntary voiding involves 
relaxation of the internal urethral sphincter and contraction of the detrusor muscle, thereby 
permitting micturition mediated by the parasympathetic nervous system. On the other hand, 
during storage the sympathetic fibers relax the bladder muscle and contract the internal 
sphincter, thus inhibiting micturition (199). The sensory pelvic and hypogastric nerve fibers 
transmit information about bladder fullness. 
Bladder dysfunction after RH is common, being reported by as many as 70% of those 
undergoing such treatment (199-201). Both early postoperative bladder dysfunction (increased 
post-voidal residual volume, lowered detrusor activity, reduced bladder sensation, decreased 
maximal urethral closure pressure) as well as long-term complications (such as voiding only 
with abdominal straining, a larger post-voidal residual volume (PVR), an over-active detrusor 
and urinary incontinence due to stress) are common (87, 199, 201). However, the causes of this 
bladder dysfunction have not yet been completely investigated. Studies on cadavers have 
revealed a high incidence of nerve injury in association with resection of the uterosacral and 
vesicouterine ligaments, as well as of the paracervical tissue during RH (86).  Thus, damage to 
parasympathetic nerves is believed to explain this dysfunction, at least in part (87-92). A RCT 
study from Korea reported that fewer nerves had been ablated in the patients undergoing nerve 
sparing surgery, who also had better bladder function (188). However, alternative explanations 
for bladder dysfunction include anatomical repositioning of the bladder, postoperative edema 
and inflammation, all of which decrease bladder compliance (84). 
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2.6.3.1 Assessment of bladder function 
Bladder function can be assessed subjectively with validated questionnaires. Objective 
evaluation of the bladder is performed by a standardized urodynamic examination using both 
a urethral and abdominal (placed rectally) sensors. This allows determination of urethral 
pressure, voiding volume, post-void residual volume, maximal flow rate, and voiding time. 
These measurements result in a cystometrogram (documenting the volumes associated with 
first sensation and first desire to void, bladder capacity and filling rate, potential over-activity 
of the detrusor muscle, stress incontinence, and the abdominal pressure at which leakage 












2.6.4 Bowel function 
Several studies based on patient questionnaires report impaired bowel function as a result after 
ORH.  The symptoms, including constipation, urge to defecate, flatulence and fecal 
incontinence, can be extremely stressful (204). Potential causes are surgical damage to nerves, 
as well as post-operative adhesions and fibrosis (88, 205, 206). 
2.6.5 Lymphatic function  
PLND involves the removal of lymph nodes from the external and internal iliac vessels and 
obturator space. Accumulation of lymphatic fluid and chronic inflammation in the 
subcutaneous fat is observed in 12-25% of women after RH for early cervical cancer with a 
negative impact on QoL (137, 138, 140, 141). This complication can be assessed subjectively 
by patient-reported questionnaires and objectively by measuring the circumference of the thigh 
before and after surgery. Lymphangiography may add information in select cases (207).  
 
2.7 SEX STEROID HORMONES AND CERVICAL CANCER 
2.7.1 Ovarian sex steroids 
Production of sex steroid hormones (estrogens, progesterone and androgens) by the ovaries and 
adrenal cortex is regulated via the hypothalamic-pituitary-ovarian and hypothalamic-pituitary-
adrenal axes. Gonadotropin-releasing hormone (GnRH) synthesized in the hypothalamus 
stimulates the production of both gonadotropin luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) by the pituitary. Subsequently, LH and FSH stimulate secretion of 
sex steroid hormones from the ovaries (208). Removal of the ovaries in premenopausal women 
reduces their levels of estrogen dramatically, causing postmenopausal symptoms.  
2.7.2 Anti-Müllerian hormone 
Anti-Müllerian hormone (AMH), a glycoprotein produced by the granulosa cells during the 
early development of follicles, is considered to be an indicator of the number of follicles 
remaining in the ovaries (209) and declines by 0.16 ng/mL each year among women of fertile 
age (210). Following ORH with preservation of the ovaries, the level of AMH declines by 45% 
(211), probably because the surgery impairs the blood supply to the ovaries. Study III reports 




Production of androgens (testosterone, androstenedione and dehydroepiandrosterone) by the 
ovaries and adrenal cortex is regulated by the hypothalamus. In women, approximately 25-50% 
of circulating testosterone originates from the ovaries (212) and bilateral salpingo-
oophorectomy is associated with a 15-50% decline (213, 214). Even when the ovaries are not 
removed, surgery reduces the levels of circulating testosterone in women (211), most likely 
due to impairment of the ovarian blood supply. In this context the effect of robot-assisted 
surgery has yet to be explored. 
In both men and women, testosterone plays a key role in sexual desire and arousal through its 
direct effects on the central nervous system, as well as by increasing genital blood-flow (215, 
216). At the same, a direct link between serum levels of testosterone and sexual function in 



















3 AIMS OF THE PRESENT THESIS 
 
The overall aim of this research project was to assess the oncologic and surgical outcomes 
after RRH and to investigate the functional consequences of RRH for early-stage cervical 
cancer. 
 
The specific aims were as follows: 
Study I 
• To compare RRH and ORH performed at KUH with respect to surgical and oncologic 
outcomes as well as health care costs 
Study II 
• To compare overall (OS) and disease-free survival (DFS) following ORH and RRH for 
early-stage cervical cancer at the national level 
Study III 
• To characterize the impact of RRH on sexual, bowel and bladder function, as well as 
on the lymphatic system one year after treatment 
• To assess psychological well-being one year after RRH 
• To examine the effect of RRH on ovarian function 
Study IV 
• To examine whether ablation of pelvic nerves and subjective and objective bladder 
dysfunction following RRH for early-stage cervical cancer are correlated.  
• To investigate the association between patient-reported outcomes and objective 







4 PARTICIPANTS AND METHODS 
In Sweden treatment of cervical cancer is performed at one of the 7 university hospitals (tertiary 
centers) or other regional hospitals. KUH alone serves the entire Stockholm region, with its 
current population of 2.4 million, and has treated all cases of cervical cancer among women in 
this region since 2004. 
Study I is a retrospective analysis of 304 women in the Stockholm region who underwent RRH 
or ORH. Study II involves a nationwide cohort of 864 women who underwent RRH or ORH. 
Studies III and IV are prospective follow-up studies of 26 and 27 women, respectively, in the 
Stockholm region who underwent RRH (Table 4). 
 
Table 4. Overview of Studies I-IV  
 
Variables Study I Study II Study III Study IV 
     
Type of study Register-based Register-based Prospective Prospective 
No of participants 304 864 26 27 
Setting KUH Sweden KUH KUH 
Treatment ORH/RRH ORH/RRH RRH RRH 








Type of radical 
hysterectomy1 









































1According to Querleu-Morrow (82); 2Orbit = The hospital data base for surgical procedures; 
3LUTSqol and FLUTS 
KUH = Karolinska University Hospital; ORH open radical hysterectomy; OS = Overall Survival; 





4.1 PARTICIPANTS AND SETTING 
The characteristics of the patients involved in Studies I and II are shown in Table 5, with 
Table 6 presenting the same information for Studies III and IV.  
 
 
Table 5. Patient and tumor characteristics Studies I and II 
 
Variables Study I (n=304) Study II (n=864) 
Treatment (n) ORH (155) RRH (149) ORH (236) RRH (628) 
     
Patients     
Age in yrs, median 
(range) 
42 (23-78) 43 (25-74) 46 (24-81) 42 (22-83) 
BMI mean (range) 24 (16-41) 24 (18-46) 24.7 (17-47)  25 (17-60) 
ASA≥3 n (%) 13 (8.4) 10 (7.4) NR NR 
     
Tumors  n (%) n (%) n (%) n (%) 
Stage (FIGO 2009)     
IA1 13 (8.4) for 
both combined 
17 (11.4) for 
both combined 
8 (3.4) 36 (5.7) 
IA2  21 (8.9) 61 (9.7) 
IB1  128 (82.3) 129 (86.6) 207 (87.7) 531 (84.6) 
IB2  7 (4.5) 1 (0.7) 0 0 
IIA 7 (4.5) 1 (0.7) 0 0 
Histology      
Squamous cell 
carcinoma 
97 (62.3) 88 (59.1) 145 (61.4) 365 (58.1) 
Adenocarcinoma  46 (29.7) 50 (33.6) 78 (33.1) 233 (37.1) 
Other  12 (7.7) 11 (7.4) 13 (5.5) 30 (4.8)2 
Size     
≤20mm 78 (50.3) 90 (60.8) 150 (63.6) 460 (73.2) 
>20 ≤40mm 66 (42.6) 49 (33.1) 70 (29.7) 151 (24) 
<40 mm 11 (7.1) 9 (6.1) 12 (5.1) 16 (2.5) 
     
 
1 According to Querleu-Morrow (82) 
2 Only adenosquamous 















Variables Study III (n=26) Study IV (n=27) 
Patients   
Age, year 44 (29-64)  43 (18.5-33.6) 
BMI 27 (19-39) 43 (18.5-33.6) 
Performance status ASA 1 (1-3)1 ECOG 0 (0-0)2 
Lymph node yield 18 (11-55) NR 
   
With partner at baseline  24 (92) 21 (78) 
Single at baseline 2 (8) 6 (22) 
   
Premopausal at baseline 22 (85) 3 20 (74) 4 
Postmenopausal at baseline 4 (15) 3                                                                      7 (26) 4 
 
Tumors 




IA1 0 0 
IA2  1 (4) 2 (7.4) 
IB1  24 (92) 25 (29.6) 
IB2  1 (4) 0 
IIA 0 0 
Histology   
Squamous cell carcinoma 12 (46) 15 (55.6) 
Adenocarcinoma  13 (50)  10 (37) 
Other  1 (4) 2 (7.4) 
1 According to ASA = American Society of Anesthesiologists; 2According to EGOG = Eastern 
Cooperative Oncology Group Performance Status (0-5); 3Based on Follicle‐stimulating hormone 











4.1.1 Study I 
All women who underwent RH and PLND for early stage 1A1-IIA1 cervical cancer at KUH 
from January 2006 to December 2015 (n=309) were initially included. Restriction to tumors of 
the squamous, adenocarcinoma or adenosquamous histological subtype led to exclusion of 5 












4.1.2 Study II 
All women in Sweden older than 18 years and scheduled to undergo RH (type B or C as 
classified according to Querleu-Morrow (82)) for FIGO stage IA1-IB cervical cancer from 
January 2011 to December 2017 (n=967) were considered for inclusion. The inclusion process, 










4.1.3 Study III 
Women aged 18-75 scheduled for RRH for stage 1A1-IIA cervical cancer at KUH from 
November 2011-December 2013 were considered eligible for inclusion. The questionnaire 
used was in Swedish, and an inability to understand the Swedish language the only basis for 
exclusion. The final study population consisted of 26 patients who all underwent nerve-sparing 
modified type B Querleu-Morrow surgery (82). (Figure 9) 
 
 
BSO = bilateral salpingo-oophorectomy 





Figure 9. Flow chart illustrating the selection of patients for inclusion in Study III 
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4.1.4 Study IV 
Between July 2017 and May 2019, women between 18-75 years with presumed FIGO stage 
IA2-IBI cervical cancer (42) scheduled consecutively for RRH were identified for potential 
inclusion in this study. The exclusion criteria were inability to understand the Swedish language 
or coexistence of another malignancy (Figure 10). Type C1 Querleu‐Morrow RH (82) 











4.2.1 Study I 
The hospital database for surgery (ORBIT) was used to identify patients who underwent RH 
during the period 2009-2015. For this purpose, the codes for RH (LCD30, LCD31), robot-
assisted surgery (ZXC96) and pelvic lymphadenectomy (PJD55) were combined with the 
code for cervical cancer (C53.9). ORH was performed by five certified surgical 
gynecological oncologists. RRH was carried out by three surgeons well experienced in both 
types of surgery and who had performed RRH > 25 times prior to this study.  
4.2.1.1 Medical records 
Patient and tumor characteristics including the FIGO stage, histology, any adjuvant therapy, 
operation time, length of hospital stay (LOS), yield of lymph nodes, follow-up time, any need 
for transfusion, any readmission within 30 days, surgical conversions, recurrences and death 
were retrieved from medical records. Oncologic safety was assessed on the basis of lymph 
node metastasis, surgical margins, LVSI, infiltration of the cervical stroma, and requirement 
for preoperative and/or adjuvant treatment. 
4.2.1.2 Surgical complications 
To minimize subjective evaluations, complications were graded using the Clavien Dindo 
(CD) system (Table 7), which is based on the intervention required to correct the 
complication (218, 219). Since complications during the operation are not covered by this 
system, they were registered separately. 
 Table 7. Complications according to Clavien Dindo (218) 
Degree Definition 
I Any deviation from the normal postoperative course that does not require intervention or 
pharmacological treatment 
II A complication requiring pharmacological treatment 
III A complication requiring some other intervention 
IIIa A complication requiring an intervention without general anesthesia 
IIIb A complication requiring an intervention under general anesthesia 
IV A life-threatening complication  
IVa Dysfunction of a single organ  




4.2.1.3 Cost per patient 
Most of the regions in Sweden register all patient-related costs according to Cost Per Patient 
(CPP). This includes ward costs (i.e., for the staff, radiology, laboratory tests, medication) and 
costs for the operating theater, postoperative care and drugs. Earlier, based on a seven-year 
depreciation of the value of the robot and an annual performance of 350 operations, Reynisson 
and Persson estimated the cost of robot-assisted surgery (155). We used their model to calculate 
the costs related to the robotic procedures which our patients underwent. We also included 
costs for complications within 30 days after surgery. The Swedish Currency (SEK) was 
converted to US dollars (USD) using the 2013 currency rate (US $1 = 6.51 SEK). 
4.2.2 Study II 
In this nationwide population-based cohort study, the participants were identified via the 
national SQRGC. To ensure the quality and conformity of the data obtained and identify 
patients not yet registered, the relevant hospital registries were reviewed and validated. 
4.2.2.1 The SQRGC 
Providing all relevant information to the Swedish National Cancer Registry (NCR) is 
mandatory for both clinicians and pathologists. The coverage of malignant tumors is greater 
than 95% and 99% of the diagnoses have been verified  histologically (220). However, this 
registry lacks clinical data regarding treatment and follow-up, which led to the establishment 
of the SQRGC in 2008, with registration of cervical cancer starting from 2011. Patient 
consent is obtained for registration. The SQRGC is online and updated prospectively by all 
hospitals and clinics in Sweden. A manual with definitions and criteria for each variable is 
easily accessible.  
Information on any individual can be accessed using the personal identification number 
assigned to all residents in Sweden and also linked to both the NCR and the National Causes 
of Death Registry, enabling coverage, control and life-long follow-up of patients. 
Comparison of the SQRGC data on ovarian and endometrial cancer with the original medical 




4.2.2.2 Medical records 
Patient and tumor characteristics including size and margins, lymph node yield and status, and 
any recurrence and complications were extracted from their medical records. In addition, 
adjuvant therapy administered was registered. Follow-up continued until the time of death or 
October 24, 2018, whichever came first. 
4.2.3 Study III 
In connection with their first visit to the outpatient clinic to be scheduled for surgery, the 
women were asked to participate in this study. Those who agreed answered one validated 
questionnaire at baseline (prior to surgery) and one year after surgery (Figure 11). At these 






Fig 11 Timeline for Study III  
 
 
The validated questionnaire used “A study-specific questionnaire developed for women with 
cervical cancer” covers general well‐being (9 questions), sexual function (39 questions), 
bowel and urinary functions (16 questions each), and lymphatic problems (4 questions). For 
further information regarding this questionnaire, please see Paper III page 1406 









Blood samples for determination of FSH, LH, SHBG, estradiol, total testosterone, 
androstenedione and AMH were taken at the same timepoints when the questionnaires were 
completed. For details concerning the manufacturers, analytical procedures, and limits of 
detection and CVs (Table 8). The level of free testosterone was calculated with the equation of 
Södergård et al. (222), which is based on the total levels of testosterone and SHBG and an 




Table 8. Overview of the assays used in Study IV 
 










0.13 ng/mL 3.7% 4.4%  
FSH time‐resolved 
fluoroimmunoassay 














0.1 nmol/L 6% (intra and inter CV 
combined) 
Estradiol Electrochemiluminescence 150 pmol/L 3.0% 4.5% 
SHBG electrochemiluminescence 0.35 nmol/L 1.3% 2.4% 
 
AMH = Anti-Müllerian hormone; FSH = follicle-stimulating hormone; LH = luteinizing hormone; 














4.2.4 Study IV 
In connection with their visit to the outpatient clinic to schedule surgery, the women were 
informed about this study. Those who agreed to participate answered two validated 
questionnaires (ICIQ-LUTSqol and ICIQ-FLUTS) regarding bladder function and quality of 
life at baseline (prior to surgery) and 2-3 weeks (+/- 3 days), 3 months (+/- 2 weeks) and 12 
months (+/- 4 weeks) after surgery (Figure 12). At these same time-points, they filled in lists 
regarding micturition and underwent bladder function tests (urodynamics). At surgery, biopsies 
were taken from six places along the resection line of the uterus (bilateral at the sacrouterine 
and vesicouterine ligaments and paracervical tissue), which were stained with S-100 (an 





Figure 12. Timeline Study IV 
4.2.4.1 Questionnaires 
Subjective evaluation of the bladder function was performed employing the Swedish version 
of the Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) and Quality of Life (ICIQ-
LUTSqol) modules of the International Consultation on Incontinence Questionnaire. The 
validated ICIQ-FLUTS questionnaire consists of 12 questions divided into three domains, 
where symptoms of filling are rated on a scale of 0-16, voiding symptoms on a scale of 0-12, 
and symptoms of incontinence from 0-20 (223). In addition, a scale of 0-10 is used to assess 
the degree of personal distress caused by each symptom. 
The 19 items of the validated ICIQ-LUTSqol questionnaire (224) assess the impact of urinary 
incontinence and other urinary problems on physical and social life, personal relationships, 
emotions and sleep. All questions are scored as 1-4 (not at all/never, slightly/sometimes, 
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moderately/often, a lot/all the time), with the three items concerning personal relationships also 
including “not applicable” as an alternative. The overall final score ranges from 19-76, with 
higher values indicating a greater impact on QoL. Finally, one last question concerns the extent 
to which the urinary symptoms interfere with everyday life, with scoring form 0 (not at all) to 
10 (maximally). Each of these questionnaires takes about 20 minutes to fill in and they were 
completed at home. 
Clinically minimal important difference (MID) has previously been defined as a change of 
more than 6 points in the LUTS-qol (225). 
4.2.4.2 The VAS scale  
In connection with these investigations, the pain experienced by each subject was assessed on 
the visual analog scale (VAS) commonly used to evaluate subjective pain intensity in clinical 
trials. The patient indicates the intensity of her pain by placing a mark at the appropriate point 
on a 100-mm line representing no pain at one end and extreme pain at the other (226). 
4.2.4.3 The urodynamic investigations 
All procedures were performed while the woman was sitting up straight. The flowmetry and 
invasive UDS were carried out using the Duet MultiP device (Medtronic Inc., Minneapolis, 
MN, USA) and air-charged urethral and abdominal sensors. In connection with the invasive 
procedure one catheter with a pressure sensor was inserted into the bladder and another, in 
order to determine abdominal pressure, into the rectum. Subtraction of the abdominal pressure 
from the intravesical pressure gave the pressure generated by the detrusor. 
For the performance of cystometry, the bladder was filled (40 ml/min) with saline at body 
temperature, with recording of any leakage (due either to the increased pressure or poor 
sphincter function) and of the subsequent time-points at which the first sensation, first desire 
to void and strong desire to void were experienced. Changes in detrusor pressure, detrusor 
overactivity and low compliance of the bladder were noted. Thereafter, the patient was allowed 
to void and the pressure-flow monitored as an indicator of contraction of the detrusor, as well 
as the resistance of the outlet. As a measure of the strength of bladder contraction, the bladder 
contractility index (BCI) was determined using the formula pDet@Qmax+5Qmax. Bladder 




The results of all urodynamic investigations were reviewed for potential errors and 
inconsistencies by the same experienced urologist. 
4.2.4.4 Nerve count 
Following surgery, six areas at the resection margin of the uterus (bilateral at the sacro-uterine 
ligaments, vesico-uterine ligaments and paracervical tissue) were marked and the specimens 
then transported immediately to the laboratory at the Department of Pathology, where bilateral 
biopsies were taken from each of the three regions. The longitudinal paracervical tissue was 
labeled 2 cm lateral to the isthmus of the uterus. The nerve fibers in microscopic sections of 
the full-length biopsies were stained for the S-100 protein, a general marker for nerves (Figure 
13) and then counted by an experienced pathologist who was blinded to the clinical information 
and surgical protocol. The nerves were categorized as small (<100 µm in length) or large (>100 














Figure 13. Staining of nerves (longitudinal section at the top left and right and cross-





4.3 STATISTICAL ANALYSIS 
4.3.1 Study I 
Student´s t-test was used for comparison of continuous variables and Fisher´s exact test for 
discrete variables. Risk factors for recurrence were analyzed by Cox regression. In all cases, 
statistical significance was defined as p <0.05 and statistical analysis performed using the IBM 
SPSS for Windows software, version 23.0 (IBM Corp., Armonk, NY, USA). 
4.3.2 Study II 
OS and DFS were examined with Cox and propensity score regression analysis, as well as 
univariable multivariable regression analysis. 
For comparison of continuous variables, student´s t-test was applied, while categorical 
variables were evaluated using Pearson’s chi-squared test or Fisher’s exact test, depending on 
the size of the category.  
The Kaplan Meier approach (228) was used to estimate survival. In addition, the proportional 
hazards model was used to estimate HRs for each of the following variables: age, grade and 
size of the tumor, lymph-vascular space invasion (LVSI), lymph node status and primary 
treatment.  
The difference in survival following ORH and RRH was estimated using a proportional hazard 
model (229) with matched data. Potential bias in this estimate was minimized by propensity 
score matching (230) that took age, grade and size of the tumor, LVSI, lymph node status, 
primary treatment and year of diagnosis into consideration.  
In all cases, the R statistical software, version 3.5.1, was employed for statistical analysis and 
a p-value less than 0.05 was considered significant. The ‘Survival’ package, version 2.42.3, 
was used to estimate survival and proportional hazard and the ‘MatchIt’ package, version 3.0.2, 
to match data on the basis of the propensity score 
4.3.3 Study III 
In light of the small study population and data that were not distributed normally, non-
parametric tests were utilized. Changes in symptoms from baseline to the one-year follow-up, 
as indicated by the answers to the questionnaire, were analyzed and compared employing a 
sign test. This test reveals differences within a group, with each participant acting as her own 
control. The values presented are the numbers of women exhibiting improvement, no change 
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or impairment. Also because of the small study population, a two-sided p-value of <0.01 was 
considered statistically significant.  
The changes in hormone levels from baseline to one year after treatment were analyzed with 
the Wilcoxons signed-rank test. The groups with or without intact ovarian function were 
compared using the Mann-Whitney U test.  
All statistical analyses were performed in the IBM SPSS for Windows software, versions 22.0 
and 23.0 (IBM Corp., Armonk, NY, USA). 
4.3.4 Study IV 
When relevant, the characteristics of the participants are presented as numbers (n), proportions, 
and median (range). Normal distribution of the data was confirmed by application of the 
Shapiro-Wilk´s test. The results of the questionnaires and urodynamic investigations are 
presented as medians and ranges and comparisons were performed with non-parametric tests. 
Friedman´s test was used for analysis of the questionnaire data and overall results at the 
different time-points.  The Wilcoxon sign rank test was used to compare the urodynamic 
parameters at the different time-points, as well as for post-hoc evaluation of each participant.   
A potential relationship between the numbers of nerve fibers and bladder function was explored 
by determining Spearman´s correlation coefficient. A P-value of <0.05 was considered 
statistically significant.  All statistical analyses were carried out with the IBM SPSS for 




All studies were approved by the Regional ethical review boards at Karolinska Institutet, 









5.1.1 Study I 
For patient and tumor characteristics please see Table 5. The surgical outcome of RRH was 
more favorable, with fewer intraoperative complications, shorter hospital stay and less need for 
blood transfusion, but with no difference with respect to postoperative complications (Table 
9). In addition, with RRH the lymph node yield was less (22.7% versus 28.9%), as well as the 
frequency of adjuvant treatment (20.1% versus 29.7%). The LVSI was more commonly found 
in the hysterectomy specimen after RRH (Table 10). The calculated CPP was 116,613 SEK in 
the case of ORH and 121,861 SEK for RRH (ns). 
 
 
Table 9. Surgical outcomes following ORH (n=155) and RRH (n=149). The values presented are 
means ± standard deviations or n (%). 
 ORH RRH p-value 
Duration of operation, min  197 ± 46.4 206 ± 44.6 ns 
Estimated blood loss, mL 596 ± 500 80.9 ± 79.7 <0.0001 
Length of hospital stay, days  6.3 ± 1.6 2.4 ± 1.8 <0.0001 
Lymph node yield 28.9 ± 13.3 22.7 ± 9.3 <0.0001 
Readmission within 30 days 2 (1.3) 18 (12.1) <0.001 
Intraoperative complications 15 (9.7) 4 (2.7) <0.05 
CD early I-II 58 (37.4) 56 (37.6) ns 
CD late I-II 6 (3.9) 11 (7.4) ns 
CD early  ≥IIIa 4 (2.6) 3 (2) ns 
CD late  ≥IIIa 7 (4.5) 9 (6.0) ns 






Table 10. Oncologic outcomes following ORH (n=155) and RRH (n=149).  
The values presented are n (%). 
 ORH RRH p-value 
Positive lymph nodes 22 (14.2) 13 (8.7) ns 
Lympho-vascular space 
invasion 
32 (20.6) 49 (32.5) <0.05 
Adjuvant radio-chemotherapy 46 (29.7) 30 (20.1) 0.06 
Preoperative brachytherapy 47 (30.3) 3 (2.0) <0.0001 
















ns = not statistically significant 
 
5.1.1.1 Recurrence and survival 
The overall rates of recurrence following ORH and RRH were 10.3% and 13.3%, respectively, 
with a somewhat higher, although not statistically significant incidence of loco-regional 
recurrences after RRH (Table 10). After adjusting for tumor size and histology, adjuvant 
therapy and positive lymph nodes, the HR for recurrence following RRH versus ORH was 2.13 
(95% CI, 1.06-4.26). (See Table 5 in Paper I, page 541). The localizations of the recurrences 
are documented in Table 11. 
TABLE 11. Annual numbers, localization and postoperative time-point of recurrence following ORH 
or RRH for early-stage cervical cancer. 
 ORH (total n=16) RRH (total n=20) 
Year N Localization (time-point 
in postoperative months) 
N Localization (time-point 
in postoperative months) 
2006 
 
2 distant (17, 84) - 
1 local (4)  
2007 3 distant (2, 15, 18) - 
 2 loco regional (20, 60)   
 1 local (20)  
2008 2 distant (6,35) - 
2009 2 distant (52,62) 0 
2010 1 local (7) 2 distant (22, 24) 
  1 loco regional (11) 
2011 1 local (10) 2 distant (7,41) 
  1 local (5) 
2012 0 2 distant (5, 10) 
  3 loco regional (7, 17 31) 
  4 local (3, 5, 12,17) 
2013 0 2 distant (3, 9) 
  1 local (23) 
2014 1 distant (15) 2 local (6, 10) 
2015 0 0 
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A Kaplan-Meier plot (not published elsewhere) revealed a significant difference in PFS in favor 
of ORH (82.5% versus 90.7%, log rank p<0.05) (Figure 14a). The OS for the two groups did 
not differ significantly (92.7% versus 91.1%, log rank 0.87) (Figure 14b). 
 
Figure 14a. Progression free survival (PFS) for women treated for early cervical cancer by radical 
hysterectomy with an estimated 5-year PFS of 90.7% in the open surgical cohort versus 82.5% in the 




Figure 14b. Overall survival (OS) for women treated for early cervical cancer by radical 
hysterectomy with an estimated 5-year OS of 91.1% in the open surgical cohort versus 92.7% in the 




5.1.2 Study II 
Of the 864 women included, 236 (27%) underwent ORH and 628 (73%) RRH. After propensity 
score matching, no differences between these groups with respect to age, BMI, or FIGO stage, 
histology or grade of their tumours were observed. The lymph node yields with ORH and RRH 
were 26 and 23, respectively (p<0.01), with a similar number of lymph nodes metastases in 
both cases. Following ORH, 32.2% received adjuvant therapy compared to 20.9% after RRH 
(p<0.05) and the corresponding follow-up times was 55.7 and 44.5 months (p<0.001) (Table 
5). 
5.1.2.1 Recurrence of disease 
In total, 84 (9.7%) of the patients suffered from recurrence of their cervical cancer, with no 
difference in this respect between the groups (n=0.12). Vaginal metastasis were more frequent 
after RRH (29 (35.8%) versus 13 (27.7%)), with no differences in locoregional (pelvic wall) 
metastasis (22 (27.2%) versus 12 (25.5%), respectively) or abdominal and distant metastasis.  
There were 7 port-site metastases following RRH. 
5.1.2.2 Survival 
The 5-year DFS following ORH or RRH was 84% (CI 95%, 79-90) and 88% (CI 95%, 85-91), 
respectively. After adjusting for tumour size or stratifying into surgery alone or in combination 
with adjuvant therapy, this value for the two groups did not differ. No statistical difference was 
found regarding the 5-year OS; 92% (CI 95%, 88-91) for the open and 94% (CI 95%, 91-96) 
for the robotic group respectively. After adjusting for tumour size or stratifying into surgery 
alone or in combination with adjuvant therapy, these values for the two groups did not differ. 
(Figure 3 in Paper II, page 175) 
Although the univariable analysis of OS as the end-point indicated that the grade and size of 
the tumour, LVSI, lymph node status and adjuvant therapy were all associated with poorer 
prognosis, the multivariable analysis did not indicate any such association. With DFS as the 
end-point, univariable analysis indicated that these same factors were associated with an 
increased risk of recurrence, but according to the multivariate analysis only tumour size 
(p>0.001) and grade 3 (p=0.02) were independent risk factors in this respect. (Table 2 in Paper 





5.1.3 Study III 
Of the 26 women eligible for analysis, 85% were premenopausal (as defined by serum levels 
of FSH at baseline). Twenty-one women with preserved ovaries were included in the hormone 
analysis and 16 among them who were below 45 years of age were also analysed for AMH 
(Table 6 and Figure 9).  
5.1.3.1 Functional outcomes 
One-year after undergoing RRH, 62-64% of the women experienced attenuated anxiety and 
depression (p<0.01). No significant change in sexual function, i.e., no increase in problems 
with desire, arousal and orgasm. More than 90% were sexually active one year after treatment. 
However, a tendency towards sexual distress, with more labial numbness (p=0.04) and deep 
pain during intercourse (p=0.02), was reported.  
32-35% of the women experienced deteriorated bladder function, i.e., urinary retention and the 
need to strain to initiate urination (Table 12). No problems with urinary tract infections, 
urgency or incontinence were reported. No symptoms involving the bowel, such as urgency to 
defecate, pain when defecating, or increased stool leakage were reported. However, 
lymphedema was also a significant problem one year after surgery. 
 
Table 12. Bladder function and lymphatic problems one year after RRH (n=26). 
Variable  Deterioration relative to 
baseline (%) 
p-value 
 Incomplete bladder evacuation 32 0.04 
Straining to initiate micturition 35 <0.01 
Swelling of the legs and lower 
abdomen 
46 <0.01 




5.1.3.2 Levels of sex steroid hormones 
One year after RRH serum levels of FSH and LH in women with preserved ovaries were 
elevated (p<0.01 respectively) while no significant alterations in the levels of testosterone, 
SHBG, estrogen or androstendione were observed. In women < 45 years of age the level of 




5.1.4 Study IV 
Twenty-seven women, median age 43, were eligible for analysis. For patient and tumor 
characteristics please see Table 6.  One complication >grade II, according to CD (218), was 
reported (i.e., a deep abscess in need of drainage). 
5.1.4.1 The FLUTS and LUTSqol questionnaires  
The women started with a score of 19 for the LUTSqol, indicating that they experienced few 
symptoms that affected their quality of life prior to surgery. At the first visit two weeks after 
surgery, this score had increased to 27 (p<0.05). Three months after surgery the score was 
almost normalized, but one year after treatment the LUTSqol score was again significantly 
higher than at baseline (median score 25 (p<0.05)).  
The FLUTS score demonstrated the same pattern. Two weeks after surgery, the scores for 
filling and voiding encompassed were significantly elevated (p<0.05), as well all scores three 
months after surgery (p<0.05). The symptoms connected with filling and voiding, as well as 
incontinence had improved one year after surgery, but were still increased (p<0.05). (Table 
13). Altogether, less than 25% of the subjects still experienced bladder dysfunction one year 
after surgery. 
Table 13. Scores (medians and ranges) of the questionnaires concerning subjective distress caused by 
the post-operative complications and its impact on quality of life (QoL) at the different time-points after 
surgery. 






27 (16-58)1 20 (17-53)1 25 (17-47)1 0.004 
Total distress 
caused by 
the symptoms a 
0 (0-5)2,3 3 (0-10)1 0.5 (0-9)1 0 (0-8) 0.006 
Problems with b     
      
Filling 1 (0-8)2,3,4 3 (0-10)1,3 2 (0-10)1,2 2 (0-10)1 0.002 
Voiding 0 (0-6)2,3,4 4 (0-10)1,3,4 3 (0-11)1,2 2 (0-9)1,2 <0.001 
Incontinence 0 (0-5)3,4 2 (0-10) 2 (0-11)1 1 (0-8)1 0.002 
 
a as determined by ICIQ-LUTSqol 
b as determined by ICIQ-FLUTS  
c p value assessed with the Friedman´s test for overall results at the different time-points 
Statistically significant differences (p<0.05) between the different time-points were examined for with the Wilcoxon sign 
rank test: 
1 significantly different from the corresponding value at baseline 
2 significantly different from the corresponding value at two weeks 
3 significantly different from the corresponding value at three months 




The uroflowmetry and pressure-flowmetry indicated a hypotonic bladder with a tendency 
(although not statistically significant) towards increased capacity and voided volume. 
Moreover, the mean maximal flow rate (MFR) in connection with spontaneous micturition 
tended to be slower two weeks after surgery, suggesting that the contractility of the bladder 
was reduced. There was a tendency towards delayed sensations, as well as increased 
cystometric capacity during the entire follow-up period.  
The pressure-flowmetry showed an impairment in the maximal detrusor pressure associated 
with micturition after surgery that remained throughout the study period (p<0.05). This 
procedure also revealed a significant increase in the residual volume after one year. At the 12-
month follow-up, one woman had developed detrusor overactivity and another leakage of 








Figure 15. Flowmetry and pressure-flow curves for one patient in connection with all four visits.   
In connection with visit 1, flowmetry and pressure-flow were normal. At the time of visit 2, the flowmetry 
revealed fractionated voiding and the pressure-flow study indicated that detrusor contraction was 
diminished in both strength and duration.  This same pattern was apparent at visit 3. By visit 4, one 
year post-surgery, the strength and duration of detrusor contraction had improved. 
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Table 14. Urodynamic characterization of the women who underwent RRH prior to and at various time-
points after the operation. The values presented are medians (ranges). 
 
 
  Before RH 2 weeks after RH 3 months after RH 1 year after RH 
N 8 5 6 7 
VAS 0 (0-3)2,3 2 (0-4)1,3 0 (0-6)1,2 0 (0-5) 
Uroflowmetry     
Voided volume (ml) 92 (26-511) 96 (17-251) 148.5 (64-189) 227 (11-538) 
MFR (Qmax in ml/s) 21.3 (4.2-24.8) 11 (5.9-35.1)4 24.4 (5-27.6) 26.6 (1.8-43.1)2 
 n (%) n (%) n (%) n (%) 
 PRV (ml) 4.4 (0-34) 0 (0-8) 15 (0-40) 5 (0-45) 
Cystometry (ml)     
First sensation  203 (77-248) 202 (65-296) 213 (86-698) 244 (103-322) 
First desire to void 278 (150-337)3 304 (178-351) 295 (206-699)1 309 (190-562) 
Strong desire to void 362 (232-676) 381 (262-588) 399 (337-700) 500 (210-578) 
Cystometric capacity  366.5 (248-677) 386 (274-597) 404 (340-700) 511 (395-597) 
Pressure-flow     
Voided volume (ml) 356 (249-617) 450 (225-537) 499 (335-700) 537 (239-587) 
Maximal detrusor 
pressure 
28 (22-47)2,3,4 12.5 (5-40)1 20 (5-38)1 17 (2-26)1 
MFR (ml/sec) 21 (10.9-26.4) 24.9 (17-28.6) 20.4 (10-35.7) 18.6 (12-25.1) 
PRV (ml) 6.5 (0-199)4 49.5 (0-123) 9 (0-128) 144 (0-250)1 
BCI 130 (84.5-159)4 140.5 (95-169) 131 (60-185.5) 112.5 (62-143)1 
BVE 97 (56-100)4 87.8 (80.8-100) 98 (80-100) 80 (46.6-100)1 
 
 
VAS=Visual Analog Scale, MFR=Maximal flow rate; PRV=Postvoid residual volume (ml); 
BCI=Bladder contractility index; BVE=Bladder voiding efficiency  
 
Statistical significance (p<0.05) was assessed with the Wilcoxon sign rank test  
1 significantly different from the corresponding value at baseline 
2 significantly different from the corresponding value at two weeks 
3 significantly different from the corresponding value at three months 










In contrast to the introduction of new pharmacological treatments, implementation of novel 
surgical modalities is never preceded by safety studies. The inherent nature of surgical 
treatment, where the operator proficiency is paramount, necessitates a gradual assessment of 
novel technologies. Robot-assisted laparoscopy is no exception and the development has been 
driven by individual surgeons and perceived benefits often exaggerated. In addition, marketing 
strategies by the industry have a major impact. RCTs constitute post-hoc evidence and the 
relevance for procedural interventions has been questioned.  Finally, cost consciousness is 
essential to ensure acceptance of novel treatment modalities. 
The overall aim of the current project was to establish the oncologic safety and to assess long-
term functional outcomes of RRH for the surgical treatment of early stage cervical cancer. To 
assess the oncologic and surgical outcomes after RRH, we performed two population-based 
cohort studies (Study I and II). In our regional analysis (Study I), RRH was associated with an 
increased risk of recurrence whereas the nationwide study (Study II) showed no difference 
between RRH and ORH. Similar postoperative morbidity and health care costs were observed 
in Study I but intraoperative adverse events were less by RRH.  
In Study III and IV, only minor effects on sexual function were reported, but bladder 
dysfunction and lymphedema remained significant consequences after RRH. The cause of 
functional impairment after RRH cannot be explained by nerve ablation alone and should be 
further investigated. Prospective trials concerning the oncologic safety of RRH are needed. 
6.1 STUDIES I AND II 
Before the publication of the LACC-trial in 2018, a number of observational studies 
demonstrated reassuring oncologic safety of MIS/RRH compared to ORH (102, 107, 116, 118, 
123-125). Study I presented in this thesis was one of the first retrospective analysis to suggest 
inferior survival after RRH. Certainly, publication bias is a well-known phenomenon after 
negative study outcomes and is likely more frequent when expensive technology is evaluated 
(134). After the LACC-trial was published, inferior oncologic outcome after MIS has been 
reported repeatedly (129-133, 231-234). In this perspective, the results from our nationwide 
study stand out with no observed survival differences between RRH and ORH. Similar data 
has recently been reported from Denmark and the two studies together comprise close to 2000 
women from similar settings (235). In contrast to most participating countries in the LACC-
trial, Swedish and Danish cancer care is highly centralized and treatment principles adhere to 
national guidelines. In addition, very few women underwent conventional laparoscopy and 
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reporting to national quality registries is mandatory in both countries. Although observational 
studies typically are considered hypothesis generating, it could be argued that large population-
based studies reflect “real world data”. However, data from the SQRGC was restricted to 2011-
2017 and earlier data was not available in the analysis. Indeed, the discrepancy between the 
oncologic outcome in the population-based Studies I and II is probably explained by selection 
bias, as the data source in the regional study included all procedures from 2009 and onwards.  
In Study I, almost twice the recurrence rate was observed in the first 50 RRH compared to last 
50. Taken together, our data from the observational studies suggest that RRH is non-inferior to 
ORH if the initial learning-curve is omitted. Methodological differences between the 
Scandinavian studies precludes direct comparisons and a “hidden” learning-curve cannot be 
ruled out in the Danish study. Adoption of novel techniques is always accompanied by an initial 
learning phase before a plateau, representing proficiency, is reached. However, the impact of 
surgical training has typically focused on perioperative outcomes including operative time, 
blood loss and complications (236). The results from Study I and II are supported by a recent 
single-center study from the Netherlands where the authors observed an institutional learning-
curve of at least 61 cases before an initial harm of RRH was neutralized (237). Preliminary data 
on the RRH learning-curve from Sweden suggest that in addition to a higher recurrence rate, a 
different pattern with more advanced, abdominal recurrences occurred in the early phase 
(unpublished data). Moreover, a retrospective analysis of laparoscopic radical prostatectomy 
indicated that the risk for recurrence within 5 years was approximately 10% higher if the 
operation was performed by surgeons with the least experience (238). Although no such 
comparison regarding RRH has been performed, mortality appears to be higher if the 
gynecological surgeon performs less than 12 procedures annually (239).   
The assessment of operator competency in RCTs for procedural interventions is clearly of 
utmost importance to avoid type II errors. In the LACC-trial, proficiency was subjectively 
evaluated through analysis of videos submitted by participating surgeons. However, the 
LACC-trial was initiated in 2008 when few surgeons had gained sufficient experience from 
minimally invasive radical hysterectomy. RH by conventional laparoscopy is generally 
considered to be one of the most demanding surgical procedures in gynecologic oncology and 
considering the rarity of early stage cervical cancer in most developed countries, the learning-
curve ought to be substantial. The observed clustering of recurrences to 14 of the 33 
participating centers in the LACC-trial reinforces the impression that surgical proficiency was 
inadequate in many institutions.  
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Other potential causes for inferior survival after MIS have been discussed extensively. 
Preclinical studies have suggested that the CO2-gas used to create pneumoperitoneum during 
MIS may promote the implantation of cancer cells in the peritoneum (240-242). However, this 
has not been confirmed in humans. Further, the final step of the RH by MIS typically includes 
intracorporeal colpotomy with exposure of the cervix in the pelvis, which may increase the risk 
of recurrence (243, 244). Köhler and co-workers recently reported data using a hybrid 
technique where the vagina was closed prior to laparoscopic RH with survival outcomes 
comparable with those from the open arm in the LACC-trial (245). 
Intrauterine manipulators are widely used to position the uterus during surgery and the use has 
been proposed to exert an impact on oncologic outcomes (246, 247).  A recent retrospective 
multicenter analysis from Europe included 693 women that underwent RH 2013-2014 and 
demonstrated an increased risk of recurrence in the MIS group (HR, 2.76; Cl 1.75-4.33) when 
a uterine manipulator was used (248). Consequently, the use of intrauterine manipulators 
during MIS for cervical cancer is discouraged but has never been part of RRH in Scandinavia.  
In contrast to most previous studies (152-154) no difference in health care costs was observed 
between RRH and ORH in Study I. This is in agreement with a previous study from Lund 
where cost neutrality was reached after 90 cases (155). Study I also demonstrated the benefits 
from the robotic technique including shorter hospital stay, less blood loss and better 
perioperative outcomes in line with previous research (65, 101, 107, 110, 115-122). Indeed, 
less intraoperative adverse events were observed after RRH in Study I, suggesting that the 
superior precision of robot-assisted surgery facilitates complex dissection in high-volume 
settings. On the other hand, vaginal cuff dehiscence with a partial or complete disruption, 
occurred in five women. This complication is more common after RRH, probably due to the 
more extensive use of electrocoagulation and/or inappropriate  suturing technique (249). 
With the increased awareness of the potentially harmful effects of MIS, the lack of apparent 
benefits in terms of improved QoL and perioperative morbidity reported from the LACC-trial 
is of particular concern (135, 179).  Robot-assisted laparoscopy is generally considered the 
most expensive surgical modality and clear benefits should be expected. Two RCTs constitute 
the basis for the current recommendation to treat endometrial cancer by MIS since both 
demonstrated superior outcomes after MIS (97, 98). Differences in patient characteristics 
between the diseases may account for the absence of benefits observed in the LACC-trial with 
younger and less obese women treated for cervical cancer. However, the negative secondary 
outcomes in the LACC-trial may reflect inadequate proficiency and “true” effects of MIS on 
adverse events went unnoticed. 
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In summary, Study I and II suggest that RRH is safe for the management of early stage cervical 
cancer once the surgeons have reached adequate proficiency. Awareness of the learning-curve 
for any new treatment modality is critical and future trials should carefully address this aspect. 
Cost-effectiveness of RRH can be achieved, especially in countries with centralized cancer 
care. Future trials need to demonstrate substantial benefits of MIS to justify the continued use 
of the technology. The continuous development of the robotic platform will hopefully 
incorporate novel technologies that facilitates surgery and improves survival. 
 
6.2 STUDIES III AND IV 
6.2.1 Psychological quality of life   
Findings regarding psychosocial well-being after treatment for cervical cancer treatment vary 
considerably due to differences in the questionnaires employed, follow-up times, patient groups 
and modes of treatment (167, 168). In Study III we evaluated different aspects of QoL with a 
questionnaire that had been subjected to careful clinimetric validation specifically with regards 
to patients with cervical cancer (165, 166). 
In patients with early-stage cervical cancer, no significant effect of RRH were found on 
physical or psychological well‐being, vitality, feeling of femininity, other's perception of their 
femininity, self‐image, or satisfaction with sexual function. This lack of significant effects 
could be due to the small number of patients and/or the fact that these aspects of QoL may be 
of lesser importance and easier to cope with than anxiety and depression. 
The increases of 62% and 65% in the levels of anxiety and depression, respectively, observed 
one year after RRH are in agreement with several other reports on cancer survivors (170, 250). 
Furthermore, the mental fatigue often reported by survivors after treatment for cervical cancer 
is an important cause of increased sick leave and loss of work several years later (251). 
Moreover, most of our subjects were premenopausal and fear of becoming infertile may have 
exacerbated their anxiety and depression. 
A diagnosis of cancer can lead to stress in any relationship. Survivors of cervical cancer are at 
increased risk of divorce (173) with associated implications for psychosocial well-being. In 
Study III, 92% of the women were involved in a steady relationship prior to surgery, but only 
81% had a partner one year after treatment.  
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6.2.2 Functional outcomes after RRH 
With surgical treatment the goal is to maximize the oncologic outcome while minimizing 
impairment of the patient´s QoL. Although the improved visibility and precision offered by 
RRH is believed to help spare nerves, many patients who undergo this type of surgery still 
experience sexual and bladder dysfunction, as well as lymphatic edema, with significantly 
impaired psychological well-being and HR-QoL. We propose that an explanation for these 
problems is damage to autonomic nerves in the pelvis, in combination with vaginal fibrosis and 
PLND. However, other factors, including an altered anatomy, reduced vaginal blood flow, 
inflammation and postoperative pain may also play a role. 
Bladder dysfunction remains one of the predominant side-effects following RH, regardless of 
surgical approach, as confirmed in Studies III and IV, where many of our patients still suffered 
of such dysfunction one year after surgery. Urological morbidity may affect daily QoL (204). 
Unfortunately, urinary dysfunction may go untreated simply because women are too 
embarrassed to report this condition spontaneously to their physician (252). Moreover, in 
connection with follow-up after surgery for cervical cancer, the primary focus is on the efficacy 
of the treatment and complications are not always dealt with adequately. To deal with this 
potential reduction in QoL due to bladder dysfunction it is essential both to inform women 
prior to RH that difficulties in voiding are common afterwards, as well as to take this potential 
complication into consideration during follow-up. dysfunction (253, 254). 
In Study IV we found that as determined with the LUTS, QoL was lowered two weeks after 
surgery, then almost normalized 3 months post-operatively, but had deteriorated significantly 
again at the time of the one-year follow-up. Interestingly, the score for symptoms was most 
pronounced two weeks after surgery and thereafter gradually improved, although never 
returning to the pre-operative status. However, there was no statistically significant correlation 
between the scores for symptoms and QoL.  
In particular, the improvement in LUTSqol observed 3 months post-operatively was not 
associated with a decrease in symptoms related to filling, voiding and incontinence (as 
indicated by the FLUTS score). At the one-year follow-up, LUTSqol had declined, even though 
there was no change in symptoms. At least in part, this might reflect the fact that although the 
women were pleased that their symptoms had subsided at three months compared to after two 
weeks postoperatively, after one year with no further reduction in symptoms they had 
difficulties coping with the possibility of no further improvement. It is also worth noting that 
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some patients experienced several symptoms that exerted very little effect on their QoL, 
perhaps due to better coping strategies. 
In many examinations, the pressure-flow examination revealed that the bladder had become 
hypotonic after RRH. For many of the women contraction of their detrusor was weakened one 
year after surgery, but in connection with the free flowmetry, they could compensate for this 
by straining or simply relaxing their pelvic floor, thereby still attaining high maximal flow 
rates. Therefore, the bladder contractility index (BCI) turned out not to be useful in our study, 
since this parameter is dependent primarily on the maximal flow rate and not on the strength 
of detrusor contraction.  
In addition, we noted that leakage became more common one year after surgery. This 
observation may reflect a hypo-contractile bladder due to weakening of the pelvic floor as a 
result of the straining to void.  
We found no correlation between the number of autonomic nerves ablated and bladder 
dysfunction. This does not exclude the possibility that nerve damage has some bearing on 
bladder dysfunction but indicates that other factors may be of greater importance. In Study IV, 
the acceptable residual volumes for some of the women in connection with catheter extraction 
5 days postoperatively were surprisingly large, which might also have influenced bladder 
function later on. Prolonged catheterization and increased awareness of residual urinary 
volume may prevent impairment of the detrusor musculature. In addition, compensatory 
straining at voiding may exaggerate bladder dysfunction and increase the risk of subsequent 
incontinence.  
Finally, the cause of postoperative bladder dysfunction appears to be multifactorial and a 
combination of preventive measures and raised awareness of early symptoms may reduce the 
functional consequences of RH for early stage cervical cancer. It is essential in the 
postoperative phase to avoid bladder overdistention, since damage to the muscle results in 
fibrosis and weakness in the contraction of the muscle. In addition, the patient should be 
instructed to refrain from straining since there is a risk of development of urine incontinence 
(84).  
The findings of studies regarding sexual function in survivors of cervical cancer are 
contradictory, observing no deterioration (255) or impairment and associated lowering of QoL 
(184). However, longitudinal follow-up does reveal problems in this respect after treatment. 
Jensen and colleagues described that following RRH for earl-stage cervical cancer, women 
reported significant vaginal problems such as dyspareunia for as long as three months 
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afterwards, as well as a negative impact on sexual interest and lubrication for up to two years 
(181). 
Several studies on nerve sparing RH have shown an improvement in outcome regarding sexual 
function (256-258). In our studies RRH exerted less impact on sexual function than has 
previously been reported following ORH (88, 166, 181, 259). The only symptoms of sexual 
distress experienced one year after RRH in Study III were numbness of the labia and deep 
dyspareunia. The labial numbness may have resulted from damage to branches of the 
genitofemoral nerve that occurred during the PLND, whereas shortening of the vagina and 
fibrosis may lead to deep pain upon vaginal penetration during intercourse.  Many of the 
women reported a feeling of a short vagina.  
In previous studies (88, 166, 187, 258) impaired arousal and orgasm were observed following 
ORH, probably due to surgical trauma to autonomic nerves, with subsequent reductions in 
vaginal blood flow and lubrication. Except for less satisfactory orgasms (P = 0.03), which may 
be explained by dyspareunia, we found no changes in arousal or the capacity for orgasm one 
year after RRH. Therefore, we propose that RRH may facilitate preservation of nerves that play 
an important role in sexual function. 
Following ORH, symptoms of bowel dysfunction such as constipation, flatus and fecal 
incontinence have been reported (204, 205). Interestingly, none of these problems was reported 
by the women involved in Study III. We hypothesize that the type B RRH utilized (82), for 
lateral and posterior dissection of the parametria in this study explains this difference.  More 
extensive dissection may result in increased bowel dysfunction.  
Lymphedema is common after PLND (18%‐40%), due to disruption of the routes for lymphatic 
drainage (137, 138). This symptom can be disabling, lowering QoL and, unlike other functional 
problems worsens with time (169, 170, 260). In our case 46% of the women reported more 
swelling of the legs and/or abdomen one year after RRH with PLND (Study III). It might be 
possible to reduce the frequency of lymphedema by employing the SNL technique instead of 
complete lymphadenectomy.  
In Study III we found elevated serum levels of FSH and LH (p<0.01) and a decline in the 
serum levels of estradiol (ns) in premenopausal women following RRH with preservation of 
the ovaries. This suggests an adverse effect on the blood supply to the ovaries. Approximately 
one-third of the ovarian blood supply comes from the uterine artery, which is closed by 
diathermy during the operation. However, serum levels of FSH and estradiol vary during the 
 
 61 
menstrual cycle and since blood samples were not taken standardized according to the 
menstrual cycle, these findings should be interpreted with caution.  
Moreover, we observed a significant lowering of median serum levels of AMH one year after 
RRH (by 0.26 ng/mL) versus an annual average decrease of 0.16 ng/ml in the general 
population of fertile women (210) which suggests an effect on the ovarian reserve. This result 
is in agreement with findings following ORH (211). This decline increases the risk of an early 
menopause, which may go unnoticed since women lose their period following RH.   
Androgens and, in particular, testosterone play a role in sexual function and symptoms of 
testosterone deficiency can clearly be ameliorated by testosterone replacement (261).  
However, at present very little is known about ovarian production of androgens following RH. 
Hallqvist found no association between levels of androgen and sexual dysfunction among 
women who survived cervical cancer (214). Nor did we find any reduction in the serum levels 
of either total or free testosterone or androstenedione following RRH with preservation of the 
ovaries. At the same time, even though we employed a highly sensitive assay for testosterone, 
















7 METHODOLOGICAL CONSIDERATIONS 
The methodological considerations regarding the prospective follow-up and population-based 
studies differ. In the two population-based registry studies we tried to adjust for known 
confounders by applying cox regression, but this assumes that the influence of the predictors 
on survival remains constant, at least during the study period, which is not the clinical reality. 
During both Studies I and II the management of early stage cervical cancer changed and thus 
introduced a time trend bias. As more experience was gained at KUH, RRH gradually became 
more radical (type C1 instead of type B). Furthermore, the increased usage of preoperative MRI 
allowed detection of suspected lymph node metastases, which may have led to increased use 
of primary radio-chemotherapy treatment.  
Enrollment of the patients in clinical trials, as in Studies III and IV, is challenging. The 
questionnaires may be perceived as too intimate to answer. In addition, urodynamic 
examinations can be uncomfortable and sometimes difficult to motivate. Subjective assessment 
by questionnaires is also influenced by the mood of the patient, which may be poor immediately 
after she has been diagnosed and is still experiencing symptoms from the cancer. Psychological 
and social factors may also be interdependent with the measured functional outcomes. 
7.1 SELECTION BIAS 
A selection bias was apparent between study I and II.  Since the SQRGC started in 2011 and 
did not include the first period of RRH in Sweden (performed 2005-2010), the initial learning 
curve was not included in Study II. Limited access to robotic systems in certain regions could 
have resulted in performance of ORH instead of RRH and introduced a selection bias. Further, 
in centers with both surgical techniques women with less advanced tumors may have been 
allocated for RRH. This is supported by the finding of significantly larger tumors in the ORH 
group in Study II. Further, in centers using SLN a selection bias was introduced since women 
with occult lymph node metastases detected intraoperatively were excluded from RRH. 
Therefore, more advanced stages were included in the ORH group.  
Study III enrolled 26 women out of the 64 who underwent RRH during the study period. 
Potentially, the answers to the questionnaire by those not included might have been different. 
This same limitation is associated with Study IV, where 44 women were eligible for inclusion, 
but only 27 answered the two questionnaires. It is possible, although unlikely that the outcome 
after surgery would have been different in the women not included. There are several reasons 
for the low number of participants included in Study III and IV. Women were not invited to 
 
 63 
participate, they declined, or they were lost to follow up. In addition, we excluded women who 
did not understand Swedish, which might also have introduced a selection bias.   
7.2 INFORMATION BIAS 
The use of high-quality registries in Study I and II reduced the risk of information bias. The 
database for surgery (ORBIT) at KUH includes all women undergoing surgery. The SQRGC, 
with high coverage, is linked to the NCR, with a coverage of approximately 95% (155). In 
addition, we reviewed local hospital registries and patient records manually to document 
recurrence. SQRGC data on ovarian and endometrial cancer have been validated with high 
agreement to medical records (221). Due to the retrospective nature of Study I complications 
treated in other hospitals could have been missed. 
Women who were asked to participate in Studies III and IV may have been influenced to 
respond to the questionnaires in a way that focused on symptoms that they would otherwise 
have ignored, thus reporting more problems related to sexual health, bladder function and/or 
bowel distress. 
In Study III for practical reasons the blood samples were neither taken at a specific time nor 
at a specific menstrual cycle day which could have influenced the results (262, 263). However, 
serum levels of AMH vary little over the menstrual  cycle (264), whereas both the diurnal and 
menstrual variations in serum levels of testosterone are quite large (263, 265).  
An additional potential information bias in Study III involved asking the women to answer the 
questionnaires prior to treatment for their cervical cancer, when they were distressed in a 
manner that could have influenced their responses. Also, by asking questions retrospectively 
as in this study at baseline, there is always a risk of recall bias. 
7.3 CONFOUNDERS 
In Studies I and II the accurate data obtained from the registries used (NCR; Orbit, SQRGC) 
allowed adjustment for several confounders. However, other potentially relevant confounders 
e.g., socioeconomic status, smoking, surgical skills were not possible to adjust for. 
Nevertheless, in Scandinavia we have a public health care system where socioeconomical 
status may not influence the provided treatment to the same extent. In the United States women 
who are white and have private health insurance, a higher income and more education are more 
likely to undergo MIS (2).  
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Many factors can influence sexual function, including lifestyle, medical health, cultural and 
religious beliefs (217, 266). In Studies III and IV, with a limited sample size, adjustment for 
such confounders was not possible.   
7.4 QOL ASSESSMENT  
Patient-reported outcomes are routinely assessed in clinical trials along with more traditional 
oncologic outcomes. A statistically significant difference of a measured patient reported 
outcome does not mean that the differences is of clinical importance to the patient. Another 
problem regarding patient-reported outcome is the interpretation of a change in the score. Does 
an improvement from 6 points to 3 mean the same as from 9 points to 6? For the questionnaire 
to be clinically useful the outcome measures need to have adequate validity and ability to detect 
changes following the intervention (responsiveness). To address this issue a clinical “minimal 
important difference” (MID) has been introduced to detect changes of clinical importance. For 
the LUTS questionnaire used in Study IV the clinical MID has been described as a change of 
more than 6 points in the LUTS-qol (225). 
7.5 EXTERNAL VALIDITY  
External validity concerns reproducibility and the extent to which our findings are also 
applicable to other conditions, patient-groups and/or other countries. The results from the 
population-based studies I and II could be applicable to women in other countries with similar 
standards of living and health care system. 
7.6 PRECISION 
In the population-based Studies I and II, the large size of the cohorts enhances the precision. 
In Study IV we did not show a correlation between the extent of nerve damage and bladder 
function. Further, in Study III we found no decline in serum levels of testosterone, SHBG or 
androstenedione and only minor sexual dysfunction. In these examples, a type II error may 
have been present due to the relatively limited size of the study participants and consequent 









• The data from the observational studies suggest that RRH has similar oncologic 
outcomes compared to ORH once the surgical proficiency has been established. 
 
• RRH for early stage cervical cancer has similar costs and postoperative complication 
rates, but shorter hospital stay and less perioperative advers events compared to ORH.   
 
• RRH appears to have only minor effects on sexual function, but bladder dysfunction 
and lymphedema remain a significant consequence of RRH which may impact QoL. 
 
• The cause of bladder function after RRH is multifactorial and cannot be explained by 
nerve ablation alone. Other factors may be of importance and should be further 
investigated.     
 
• Anxiety and depression were reported to a greater extent one year after surgery for early 
stage cervical cancer. 
 
• The hormone analyzes after RRH with ovarian preservation in premenopausal women 












9 FUTURE PERSPECTIVES 
 
 
• Prospective trials need to ensure the safety of RRH and establish the benefits of the 
robotic technique  
 
• Awareness of the learning-curve for any new treatment modality is critical and 
future trials should carefully address this aspect. 
 
• Optimal balance between maximal curative outcome and minimal functional 
morbidity must be established for RH. 
 
• The sentinel node technique attenuates lymphatic sequelae but additional studies 
are required to establish the oncologic safety. 
 
• To alleviate bladder dysfunction the optimal time for postoperative bladder 
catheterization needs to be explored and possible urotherapy interventions 
evaluated. A better understanding of the underlying causes, perhaps unrelated to 













10 SUMMARY IN SWEDISH (SAMMANFATTNING PÅ 
SVENSKA) 
Livmoderhalscancer är globalt den fjärde vanligaste cancerformen hos kvinnor. Hälften av 
alla som drabbas är yngre än 50 år. Sjukdomen upptäcks och behandlas i regel tidigt och mer 
än 90% kan bli botade. Livmoderhalscancer i tidigt stadium behandlas genom att operera bort 
livmodern (radikal hysterektomi) samt regionala lymfkörtlar i bäckenet, och ibland även 
äggstockarna. Komplikationer från tarm och urinblåsa är vanliga, liksom bensvullnad och 
sexuella problem.  
2005 introducerades robotassisterad laparoskopisk radikal hysterektomi (RRH) för kirurgisk 
behandling av livmoderhalscancer. RRH ansågs ha fördelar som t.ex kortare vårdtid och färre 
komplikationer jämfört med öppen radikal hysterektomi (ORH). Målet med projektet var att 
undersöka om RRH gav samma onkologiska säkerhet och var lika kostnadseffektivt som ORH. 
Dessutom följde vi kvinnornas funktionella besvär upp till ett år efter RRH. 
Studie I inkluderade 304 kvinnor med livmoderhalscancer i tidigt stadium som genomgått 
RRH (n=149) och ORH (n=155) mellan 2006-2015 vid Karolinska Universitetssjukhuset. 
Kirurgiska komplikationer, kostnader och recidiv jämfördes. Postoperativa komplikationer 
(37%) och kostnader skilde sig inte åt mellan de kirurgiska teknikerna, men kvinnor som 
opererats med RRH hade i medeltal fyra dygn kortare vårdtid. Efter korrigering av kända 
riskfaktorer för recidiv som tumörstorlek, histologisk tumörtyp och lymfkörtelstatus sågs en 
ökar risk för recidiv efter RRH (HR 2.13; 95% CI, 1.06-4.26) i jämförelse med ORH. 
I en nationell populationsbaserad studie mellan 2011-2017, innefattande 864 kvinnor med 
tidigt stadium av livmoderhalscancer (Studie II), jämfördes överlevnad mellan RRH (n=628) 
och ORH (n=236). Vi fann inte några skillnader i recidivfrekvens eller 5- års överlevnad mellan 
de kirurgiska teknikerna, även med hänsyn taget till de viktigaste prognostiska variablerna. 
Total 5-års överlevnad var 92% respektive 94% för ORH och RRH.  
I Studie III: besvarade 26 kvinnor som genomgick RRH under 2011-2013 ett validerat 
frågeformulär före, samt ett år efter operation om livskvalitet, sexuell funktion och symtom 
från tarm, urinblåsa och eventuella lymfödem. Därtill mättes könshormoner. Resultaten visade 
att RRH i liten utsträckning påverkar tarm och sexuell funktion men att störningar i 
blåsfunktion (35%), och lymfdränage i benen (46%) var vanligt ett år efter kirurgi. Även 
depression och oro var signifikant ökade ett år efter operationen. Könshormonerna minskade 
signifikant, även hos premenopausala kvinnor som fick sina äggstockar bortopererade.  
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I studie IV svarade 27 kvinnor före, samt vid upprepade tillfällen upp till ett år efter operation 
på frågor om symtom från urinblåsan, och hur det påverkade livskvaliteten.  
Urinblåsefunktionen undersöktes med objektiva metoder (urodynamik) och via kvantifiering 
av nervtrådar som delades vid operationen. Studien visade att besvären från urinblåsan beror 
på en minskad kontraktionskraft och att en del kvinnor utvecklade urinläckage som kan bero 
krystning vid miktion. Symtomen minskade dock över tid, men kvarstod hos en del. I vissa fall 
uppgav även kvinnorna en sämre livskvalitet. 
Data från våra registerbaserade studier är motstridiga, där den regionala studien visade en ökad 
risk för återfall efter robotkirurgi medan den nationella studien inte visade någon skillnad 
mellan metoderna. De olika resultaten kan bero på en inlärningskurva som ger sämre 
onkologiskt utfall när en ny operationsmetod introduceras. RRH medförde kortare vårdtid och 
färre intraoperativa komplikationer än ORH. Ingen skillnad noterades avseende postoperativa 
komplikationer och sjukvårdskostnader. RRH förefaller ha en liten effekt på sexuell funktion 
men många kvinnor har problem med blåstömning och lymfödem ett år efter kirurgi. Vi kunde 
inte visa att enbart nervskada i samband med kirurgin var orsak till blåstömningsbesvären utan 
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